SCHEMBL5156746

SCHEMBL5156746

CCc1ccc(C2SCC(=O)N2CCc2cccs2)cc1

nearest known ligand 0.56

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.55
SMN1; SMN2 Q16637 2/20 0.55
ALDH1A1 P00352 2/20 0.55
HPGD P15428 2/20 0.51
PTGS1 P23219 1/20 0.50
PTGS2 P35354 1/20 0.50
KDM4E B2RXH2 1/20 0.48
GAA P10253 1/20 0.48
MAPT P10636 1/20 0.48
MAPK1 P28482 1/20 0.48
TDP1 Q9NUW8 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
KCNA5 P22460 1/20 0.46
HTR7 P34969 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5156842 0.85 CACNA1B (0.52) LMNASMN1; SMN2ALDH1A1HPGDPTGS1
SCHEMBL5155056 0.77 MAPT (0.61) LMNASMN1; SMN2ALDH1A1HPGDPTGS1
SCHEMBL5151451 0.74 SMN1; SMN2 (0.85) LMNASMN1; SMN2ALDH1A1HPGDPTGS1
SCHEMBL5155033 0.74 PTGS1 (0.53) LMNASMN1; SMN2ALDH1A1PTGS1PTGS2
SCHEMBL8444032 0.70 PTGS1 (0.65) LMNASMN1; SMN2HPGDPTGS1PTGS2
SCHEMBL16209660 0.70 KMT2A (0.78) LMNASMN1; SMN2ALDH1A1HPGDPTGS1
SCHEMBL5156737 0.69 KMT2A (0.61) LMNASMN1; SMN2ALDH1A1HPGDKDM4E
SCHEMBL5155489 0.66 ALDH1A1 (0.56) LMNASMN1; SMN2ALDH1A1HPGDPTGS1
SCHEMBL8635567 0.66 PTGS1 (0.55) LMNASMN1; SMN2HPGDPTGS1PTGS2
SCHEMBL19306257 0.65 HTR7 (0.81) LMNASMN1; SMN2ALDH1A1PTGS1PTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7223754-B2 Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders DYNOGEN PHARMACEUTICALS, INC. (US) 2007-05-29 US disclosed
US-20070066597-A1 Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders DYNOGEN PHARMACEUTICALS, INC. (US) 2007-03-22 US disclosed
US-20050148587-A1 Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders DYNOGEN PHARMACEUTICALS, INC. (US) 2005-07-07 US disclosed
US-20050113421-A1 Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating non-inflammatory gastrointestinal tract disorders DYNOGEN PHARMACEUTICALS, INC. (US) 2005-05-26 US disclosed
WO-2004017965-A1 1,3-THIAZOLIN-4-ONES AS THERAPEUTIC COMPOUNDS IN THE TREATMENT OF PAIN IONIX PHARMACEUTICALS LIMITED (GB) 2004-03-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050113421-A1 Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating non-inflammatory gastrointestinal tract disorders TRPV2, RYR2, VDAC2 LMNA 4361/4885SMN1; SMN2 2615/4885ALDH1A1 3381/4885
US-20070066597-A1 Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders RYR2, CACNB2, CACNA1I LMNA 3554/4885SMN1; SMN2 1195/4885ALDH1A1 1370/4885
US-20050148587-A1 Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders RYR2, CACNB2, CACNA1I LMNA 3554/4885SMN1; SMN2 1195/4885ALDH1A1 1370/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.